Advertisement
Review Article| Volume 107, ISSUE 3, P397-421, May 2023

Download started.

Ok

The Past, Present, and Future of Noninvasive Test in Chronic Liver Diseases

  • Author Footnotes
    1 These authors contributed equally to this work and share first authorship.
    Douglas Chee
    Footnotes
    1 These authors contributed equally to this work and share first authorship.
    Affiliations
    Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Tower Block Level 10, 1E Kent Ridge Road, Singapore 119228, Singapore
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally to this work and share first authorship.
    Cheng Han Ng
    Footnotes
    1 These authors contributed equally to this work and share first authorship.
    Affiliations
    Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Tower Block Level 10, 1E Kent Ridge Road, Singapore 119228, Singapore
    Search for articles by this author
  • Kai En Chan
    Affiliations
    Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Tower Block Level 10, 1E Kent Ridge Road, Singapore 119228, Singapore
    Search for articles by this author
  • Daniel Q. Huang
    Affiliations
    Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Tower Block Level 10, 1E Kent Ridge Road, Singapore 119228, Singapore

    Yong Loo Lin School of Medicine, National University of Singapore, Tower Block Level 10, 1E Kent Ridge Road, Singapore 119228, Singapore

    National University Centre for Organ Transplantation, National University Health System, Tower Block Level 10, 1E Kent Ridge Road, Singapore 119228, Singapore
    Search for articles by this author
  • Margaret Teng
    Affiliations
    Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Tower Block Level 10, 1E Kent Ridge Road, Singapore 119228, Singapore

    Yong Loo Lin School of Medicine, National University of Singapore, Tower Block Level 10, 1E Kent Ridge Road, Singapore 119228, Singapore

    National University Centre for Organ Transplantation, National University Health System, Tower Block Level 10, 1E Kent Ridge Road, Singapore 119228, Singapore
    Search for articles by this author
  • Mark Muthiah
    Correspondence
    Corresponding author.
    Affiliations
    Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital, Tower Block Level 10, 1E Kent Ridge Road, Singapore 119228, Singapore

    Yong Loo Lin School of Medicine, National University of Singapore, Tower Block Level 10, 1E Kent Ridge Road, Singapore 119228, Singapore

    National University Centre for Organ Transplantation, National University Health System, Tower Block Level 10, 1E Kent Ridge Road, Singapore 119228, Singapore
    Search for articles by this author
  • Author Footnotes
    1 These authors contributed equally to this work and share first authorship.
Published:February 20, 2023DOI:https://doi.org/10.1016/j.mcna.2022.12.001

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Medical Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Moon A.M.
        • Singal A.G.
        • Tapper E.B.
        Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis.
        Clin Gastroenterol Hepatol. 2020; 18: 2650-2666
        • Sepanlou S.G.
        • Safiri S.
        • Bisignano C.
        • et al.
        The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017.
        Lancet Gastroenterol Hepatol. 2020; 5: 245-266
        • Riazi K.
        • Azhari H.
        • Charette J.H.
        • et al.
        The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis.
        Lancet Gastroenterol Hepatol. 2022; 7: 851-861
        • Fazel Y.
        • Koenig A.B.
        • Sayiner M.
        • et al.
        Epidemiology and natural history of non-alcoholic fatty liver disease.
        Metabolism. 2016; 65: 1017-1025
        • Ng C.H.
        • Lim W.H.
        • Lim G.E.H.
        • et al.
        Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis.
        Clin Gastroenterol Hepatol. 2022; 0https://doi.org/10.1016/J.CGH.2022.04.014
        • Yano M.
        • Kumada H.
        • Kage M.
        • et al.
        The long-term pathological evolution of chronic hepatitis C.
        Hepatology. 1996; 23: 1334-1340
        • Lackner C.
        • Spindelboeck W.
        • Haybaeck J.
        • et al.
        Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease.
        J Hepatol. 2017; 66: 610-618
        • Kim N.J.
        • Vutien P.
        • Cleveland E.
        • et al.
        Fibrosis Stage-specific Incidence of Hepatocellular Cancer After Hepatitis C Cure With Direct-acting Antivirals: A Systematic Review and Meta-analysis.
        Clin Gastroenterol Hepatol. 2022; https://doi.org/10.1016/J.CGH.2022.04.013
        • Bedossa P.
        • Dargère D.
        • Paradis V.
        Sampling Variability of Liver Fibrosis in Chronic Hepatitis C.
        Hepatology. 2003; 38: 1449-1457
        • Davison B.A.
        • Harrison S.A.
        • Cotter G.
        • et al.
        Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials.
        J Hepatol. 2020; 73: 1322-1332
        • Muthiah M.D.
        • Sanyal A.J.
        Burden of Disease due to Nonalcoholic Fatty Liver Disease.
        Gastroenterol Clin North Am. 2020; 49: 1-23
        • Zheng Q.
        • Zou B.
        • Wu Y.
        • et al.
        Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B.
        Aliment Pharmacol Ther. 2021; 54: 1100-1109
        • Modaresi Esfeh J.
        • Ansari-Gilani K.
        Steatosis and hepatitis C.
        Gastroenterol Rep (Oxf). 2015; : gov040https://doi.org/10.1093/gastro/gov040
        • Asselah T.
        • Rubbia-Brandt L.
        • Marcellin P.
        • et al.
        Steatosis in chronic hepatitis C: Why does it really matter?.
        Gut. 2006; 55: 123-130
        • Siphepho P.Y.
        • Liu Y.T.
        • Shabangu C.S.
        • et al.
        The impact of steatosis on chronic hepatitis c progression and response to antiviral treatments.
        Biomedicines. 2021; 9https://doi.org/10.3390/biomedicines9101491
        • Negro F.
        Mechanisms and significance of liver steatosis in hepatitis C virus infection.
        World J Gastroenterol : WJG. 2006; 12: 6756
        • Israelsen M.
        • Juel H.B.
        • Detlefsen S.
        • et al.
        Metabolic and Genetic Risk Factors Are the Strongest Predictors of Severity of Alcohol-Related Liver Fibrosis.
        Clin Gastroenterol Hepatol. 2021; https://doi.org/10.1016/j.cgh.2020.11.038
        • Bedogni G.
        • Bellentani S.
        • Miglioli L.
        • et al.
        The fatty liver index: A simple and accurate predictor of hepatic steatosis in the general population.
        BMC Gastroenterol. 2006; 6https://doi.org/10.1186/1471-230X-6-33
        • Lee J.H.
        • Kim D.
        • Kim H.J.
        • et al.
        Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease.
        Dig Liver Dis. 2010; 42: 503-508
        • Kotronen A.
        • Peltonen M.
        • Hakkarainen A.
        • et al.
        Prediction of Non-Alcoholic Fatty Liver Disease and Liver Fat Using Metabolic and Genetic Factors.
        Gastroenterology. 2009; 137: 865-872
        • Fedchuk L.
        • Nascimbeni F.
        • Pais R.
        • et al.
        Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease.
        Aliment Pharmacol Ther. 2014; 40: 1209-1222
        • Wanless I.R.
        • Lentz J.S.
        Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors.
        Hepatology. 1990; 12: 1106-1110
        • Xavier S.A.
        • Monteiro S.O.
        • Arieira C.M.
        • et al.
        US-FLI score – Is it possible to predict the steatosis grade with an ultrasonographic score?.
        Mol Genet Metab. 2021; 132: 204-209
        • Ballestri S.
        • Lonardo A.
        • Romagnoli D.
        • et al.
        Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD.
        Liver Int. 2012; 32: 1242-1252
        • Bae J.S.
        • Lee D.H.
        • Suh K.S.
        • et al.
        Noninvasive assessment of hepatic steatosis using a pathologic reference standard: comparison of CT, MRI, and US-based techniques.
        Ultrasonography. 2021; 41: 344-354
        • Hannah W.N.
        • Harrison S.A.
        Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
        Hepatology. 2016; 64: 2234-2243
        • de Moura Almeida A.
        • Cotrim H.P.
        • Barbosa D.B.V.
        • et al.
        Fatty liver disease in severe obese patients: Diagnostic value of abdominal ultrasound.
        World J Gastroenterol. 2008; 14: 1415-1418
        • Bril F.
        • Ortiz-Lopez C.
        • Lomonaco R.
        • et al.
        Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients.
        Liver Int. 2015; 35: 2139-2146
        • Strauss S.
        • Gavish E.
        • Gottlieb P.
        • et al.
        Interobserver and intraobserver variability in the sonographic assessment of fatty liver.
        Am J Roentgenol. 2007; 189: 1449
        • Hamaguchi M.
        • Kojima T.
        • Itoh Y.
        • et al.
        The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation.
        Am J Gastroenterol. 2007; 102: 2708-2715
        • Cloutier G.
        • Destrempes F.
        • Yu F.
        • et al.
        Quantitative ultrasound imaging of soft biological tissues: a primer for radiologists and medical physicists.
        Insights Imaging. 2021; 12https://doi.org/10.1186/s13244-021-01071-w
        • Gao F.
        • He Q.
        • Li G.
        • et al.
        A novel quantitative ultrasound technique for identifying non-alcoholic steatohepatitis.
        Liver Int. 2022; 42: 80-91
        • Karlas T.
        • Petroff D.
        • Sasso M.
        • et al.
        Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis.
        J Hepatol. 2017; 66: 1022-1030
        • Ferraioli G.
        • Tinelli C.
        • Lissandrin R.
        • et al.
        Interobserver reproducibility of the controlled attenuation parameter (CAP) for quantifying liver steatosis.
        Hepatol Int. 2014; 8: 576-581
        • Wong V.W.S.
        • Petta S.
        • Hiriart J.B.
        • et al.
        Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter.
        J Hepatol. 2017; 67: 577-584
        • Eddowes P.J.
        • Sasso M.
        • Allison M.
        • et al.
        Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
        Gastroenterology. 2019; 156: 1717-1730
        • Oeda S.
        • Takahashi H.
        • Imajo K.
        • et al.
        Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan® M/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: a multicenter prospective study.
        J Gastroenterol. 2020; 55: 428-440
        • Petroff D.
        • Blank V.
        • Newsome P.N.
        • et al.
        Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis.
        Lancet Gastroenterol Hepatol. 2021; 6: 185-198
        • Caussy C.
        • Alquiraish M.H.
        • Nguyen P.
        • et al.
        Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis.
        Hepatology. 2018; 67: 1348-1359
        • Zheng D.
        • Tian W.
        • Zheng Z.
        • et al.
        Accuracy of computed tomography for detecting hepatic steatosis in donors for liver transplantation: A meta-analysis.
        Clin Transpl. 2017; 31: e13013
        • Park S.H.
        • Kim P.N.
        • Kim K.W.
        • et al.
        Macrovesicular Hepatic Steatosis in Living Liver Donors: Use of CT for Quantitative and Qualitative Assessment1.
        Radiology. 2006; 239: 105-112
        • Limanond P.
        • Raman S.S.
        • Lassman C.
        • et al.
        Macrovesicular Hepatic Steatosis in Living Related Liver Donors: Correlation between CT and Histologic Findings1.
        Radiology. 2004; 230: 276-280
        • Ma J.
        • Song Z.Q.
        • Yan F.H.
        Separation of Hepatic Iron and Fat by Dual-Source Dual-Energy Computed Tomography Based on Material Decomposition: An Animal Study.
        PLoS One. 2014; 9: e110964
        • Fischer M.A.
        • Gnannt R.
        • Raptis D.
        • et al.
        Quantification of liver fat in the presence of iron and iodine: An ex-vivo dual-energy CT study.
        Invest Radiol. 2011; 46: 351-358
        • van Werven J.R.
        • Marsman H.A.
        • Nederveen A.J.
        • et al.
        Assessment of Hepatic Steatosis in Patients Undergoing Liver Resection: Comparison of US, CT, T1-weighted Dual-Echo MR Imaging, and Point-resolved 1H MR Spectroscopy1.
        Radiology. 2010; 256: 159-168
        • Tang A.
        • Desai A.
        • Hamilton G.
        • et al.
        Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease.
        Radiology. 2015; 274: 416-425
        • Park C.C.
        • Nguyen P.
        • Hernandez C.
        • et al.
        Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease.
        Gastroenterology. 2017; 152 (e2): 598-607
        • Bannas P.
        • Kramer H.
        • Hernando D.
        • et al.
        Quantitative magnetic resonance imaging of hepatic steatosis: Validation in ex vivo human livers.
        Hepatology. 2015; 62: 1444-1455
        • Yano M.
        • Kumada H.
        • Kage M.
        • et al.
        The Long-Term Pathological Evolution of Chronic Hepatitis C.
        Hepatology. 1996; 23: 1334-1340
        • Younossi Z.M.
        • Stepanova M.
        • Rafiq N.
        • et al.
        Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality.
        Hepatology. 2011; 53: 1874-1882
        • McPherson S.
        • Stewart S.F.
        • Henderson E.
        • et al.
        Simple noninvasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease.
        Gut. 2010; 59: 1265-1269
        • Wong V.W.S.
        • Wong G.L.H.
        • Chim A.M.L.
        • et al.
        Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis.
        Am J Gastroenterol. 2008; 103: 1682-1688
        • Sterling R.K.
        • Lissen E.
        • Clumeck N.
        • et al.
        Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection.
        Hepatology. 2006; 43: 1317-1325
        • Xiao G.
        • Zhu S.
        • Xiao X.
        • et al.
        Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta-analysis.
        Hepatology. 2017; 66: 1486-1501
        • McPherson S.
        • Hardy T.
        • Dufour J.F.
        • et al.
        Age as a Confounding Factor for the Accurate Noninvasive Diagnosis of Advanced NAFLD Fibrosis.
        Am J Gastroenterol. 2017; 112: 740
        • Mózes F.E.
        • Lee J.A.
        • Selvaraj E.A.
        • et al.
        Diagnostic accuracy of noninvasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.
        Gut. 2022; 71https://doi.org/10.1136/GUTJNL-2021-324243
        • Graupera I.
        • Thiele M.
        • Serra-Burriel M.
        • et al.
        Low Accuracy of FIB-4 and NAFLD Fibrosis Scores for Screening for Liver Fibrosis in the Population.
        Clin Gastroenterol Hepatol. 2021; https://doi.org/10.1016/J.CGH.2021.12.034
        • Gudowska M.
        • Gruszewska E.
        • Panasiuk A.
        • et al.
        Hyaluronic acid concentration in liver diseases.
        Clin Exp Med. 2016; 16: 523-528
        • Suzuki A.
        • Angulo P.
        • Lymp J.
        • et al.
        Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease.
        Liver Int. 2005; 25: 779-786
        • Wang Y.
        • Pan W.
        • Zhao D.
        • et al.
        Diagnostic Value of Serum Procollagen III N-Terminal Peptide for Liver Fibrosis in Infantile Cholestasis.
        Front Pediatr. 2020; 8https://doi.org/10.3389/fped.2020.00131
        • Nielsen M.J.
        • Nedergaard A.F.
        • Sun S.
        • et al.
        The Neo-Epitope Specific PRO-C3 ELISA Measures True Formation of Type III Collagen Associated with Liver and Muscle Parameters.
        Am J Transl Res. 2013; 5 (Available at:): 303-315
        • Mak A.L.
        • Lee J.
        • van Dijk A.M.
        • et al.
        Systematic review with meta-analysis: Diagnostic accuracy of pro-c3 for hepatic fibrosis in patients with non-alcoholic fatty liver disease.
        Biomedicines. 2021; 9https://doi.org/10.3390/biomedicines9121920
        • Hemmann S.
        • Graf J.
        • Roderfeld M.
        • et al.
        Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies.
        J Hepatol. 2007; 46: 955-975
        • Abdelaziz R.
        • Elbasel M.
        • Esmat S.
        • et al.
        Tissue inhibitors of metalloproteinase-1 and 2 and obesity related non-alcoholic fatty liver disease: Is there a relationship?.
        Digestion. 2015; 92: 130-137
        • Vali Y.
        • Lee J.
        • Boursier J.
        • et al.
        Enhanced liver fibrosis test for the noninvasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis.
        J Hepatol. 2020; 73: 252-262
        • Lichtinghagen R.
        • Pietsch D.
        • Bantel H.
        • et al.
        The Enhanced Liver Fibrosis (ELF) score: Normal values, influence factors and proposed cut-off values.
        J Hepatol. 2013; 59: 236-242
        • Younossi Z.M.
        • Felix S.
        • Jeffers T.
        • et al.
        Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis among Patients with Nonalcoholic Fatty Liver Disease.
        JAMA Netw Open. 2021; 4https://doi.org/10.1001/jamanetworkopen.2021.23923
        • Imbert-Bismut F.
        • Ratziu V.
        • Pieroni L.
        • et al.
        Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study.
        Lancet. 2001; 357: 1069-1075
        • Ratziu V.
        • Massard J.
        • Charlotte F.
        • et al.
        Diagnostic value of biochemical markers (Fibro Test-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease.
        BMC Gastroenterol. 2006; 6https://doi.org/10.1186/1471-230X-6-6
        • Munteanu M.
        • Tiniakos D.
        • Anstee Q.
        • et al.
        Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.
        Aliment Pharmacol Ther. 2016; 44: 877-889
        • Loong T.C.W.
        • Wei J.L.
        • Leung J.C.F.
        • et al.
        Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease.
        J Gastroenterol Hepatol (Australia). 2017; 32: 1363-1369
        • Daniels S.J.
        • Leeming D.J.
        • Eslam M.
        • et al.
        ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis.
        Hepatology. 2019; 69: 1075-1086
        • Boyle M.
        • Tiniakos D.
        • Schattenberg J.M.
        • et al.
        Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease.
        JHEP Rep. 2019; 1: 188-198
        • Papatheodoridi M.
        • Hiriart J.B.
        • Lupsor-Platon M.
        • et al.
        Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease.
        J Hepatol. 2021; 74: 1109-1116
        • Lazarus J.v.
        • Castera L.
        • Mark H.E.
        • et al.
        Real-world evidence on noninvasive tests and associated cut-offs used to assess fibrosis in routine clinical practice.
        JHEP Rep. 2022; 22: 100596
        • Wong G.L.H.
        • Chan H.L.Y.
        • Choi P.C.L.
        • et al.
        Association Between Anthropometric Parameters and Measurements of Liver Stiffness by Transient Elastography.
        Clin Gastroenterol Hepatol. 2013; 11https://doi.org/10.1016/j.cgh.2012.09.025
        • Castera L.
        • Foucher J.
        • Bernard P.H.
        • et al.
        Pitfalls of liver stiffness measurement: A 5-year prospective study of 13,369 examinations.
        Hepatology. 2010; 51: 828-835
        • Cassinotto C.
        • Erome Boursier J.
        • de L Edinghen V.
        • et al.
        Liver Stiffness in Nonalcoholic Fatty Liver Disease: A Comparison of Supersonic Shear Imaging, FibroScan, and ARFI With Liver Biopsy a he study of liver diseases t american association for.
        Hepatology. 2016; 63: 1817-1827
        • Zhou X.
        • Rao J.
        • Wu X.
        • et al.
        Comparison of 2-D Shear Wave Elastography and Point Shear Wave Elastography for Assessing Liver Fibrosis.
        Ultrasound Med Biol. 2021; 47: 408-427
        • Imajo K.
        • Kessoku T.
        • Honda Y.
        • et al.
        Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease Than Transient Elastography.
        Gastroenterology. 2016; 150 (e7): 626-637
        • Caussy C.
        • Chen J.
        • Alquiraish M.H.
        • et al.
        Association Between Obesity and Discordance in Fibrosis Stage Determination by Magnetic Resonance vs Transient Elastography in Patients With Nonalcoholic Liver Disease.
        Clin Gastroenterol Hepatol. 2018; 16 (e7): 1974-1982
        • Loomba R.
        • Adams L.A.
        Advances in noninvasive assessment of hepatic fibrosis.
        Gut. 2020; 69: 1343-1352
        • Imajo K.
        • Honda Y.
        • Kobayashi T.
        • et al.
        Direct Comparison of US and MR Elastography for Staging Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
        Clin Gastroenterol Hepatol. 2022; 20 (e11): 908-917
        • Hsu C.
        • Caussy C.
        • Imajo K.
        • et al.
        Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants.
        Clin Gastroenterol Hepatol. 2019; 17 (e8): 630-637
        • Ekstedt M.
        • Hagström H.
        • Nasr P.
        • et al.
        Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.
        Hepatology. 2015; 61: 1547-1554
        • Gidener T.
        • Yin M.
        • Dierkhising R.A.
        • et al.
        Magnetic resonance elastography for prediction of long-term progression and outcome in chronic liver disease: A retrospective study.
        Hepatology. 2022; 75: 379-390
        • Matsui N.
        • Imajo K.
        • Yoneda M.
        • et al.
        Magnetic resonance elastography increases usefulness and safety of noninvasive screening for esophageal varices.
        J Gastroenterol Hepatol. 2018; 33: 2022-2028
        • Tamaki N.
        • Kurosaki M.
        • Higuchi M.
        • et al.
        Validation of albumin, bilirubin, and platelet criteria for avoiding screening endoscopy in patients with advanced fibrosis.
        Hepatol Res. 2020; 50: 996-999
        • Unalp-Arida A.
        • Ruhl C.E.
        Noninvasive fatty liver markers predict liver disease mortality in the U.S. population.
        Hepatology. 2016; 63: 1170-1183
        • Shili-Masmoudi S.
        • Wong G.L.H.
        • Hiriart J.B.
        • et al.
        Liver stiffness measurement predicts long-term survival and complications in non-alcoholic fatty liver disease.
        Liver Int. 2020; 40: 581-589
        • Tamaki N.
        • Higuchi M.
        • Kurosaki M.
        • et al.
        Risk Difference of Liver-Related and Cardiovascular Events by Liver Fibrosis Status in Nonalcoholic Fatty Liver Disease.
        Clin Gastroenterol Hepatol. 2022; 20 (e2): 1171-1173
        • Higuchi M.
        • Tamaki N.
        • Kurosaki M.
        • et al.
        Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortality.
        Aliment Pharmacol Ther. 2022; 55: 292-301
        • Long M.T.
        • Zhang X.
        • Xu H.
        • et al.
        Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study.
        Hepatology. 2021; 73: 548-559
        • Pang J.X.Q.
        • Zimmer S.
        • Niu S.
        • et al.
        Liver Stiffness by Transient Elastography Predicts Liver-Related Complications and Mortality in Patients with Chronic Liver Disease.
        PLoS One. 2014; 9https://doi.org/10.1371/JOURNAL.PONE.0095776
        • Cardoso C.R.L.
        • Villela-Nogueira C.A.
        • Leite N.C.
        • et al.
        Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study.
        Cardiovasc Diabetol. 2021; 20https://doi.org/10.1186/S12933-021-01388-2
        • Hagström H.
        • Talbäck M.
        • Andreasson A.
        • et al.
        Ability of Noninvasive Scoring Systems to Identify Individuals in the Population at Risk for Severe Liver Disease.
        Gastroenterology. 2020; 158: 200-214
        • Schonmann Y.
        • Yeshua H.
        • Bentov I.
        • et al.
        Liver fibrosis marker is an independent predictor of cardiovascular morbidity and mortality in the general population.
        Dig Liver Dis. 2021; 53: 79-85
        • Chew N.W.S.
        • Ng C.H.
        • Chan K.E.
        • et al.
        The Fibrosis-4 (FIB-4) Index Predicts Cardiovascular Major Adverse Events and Mortality in Patients with Non-alcoholic Fatty Liver Disease.
        Can J Cardiol. 2022; 0
        • Jaruvongvanich V.
        • Wijarnpreecha K.
        • Ungprasert P.
        The utility of NAFLD fibrosis score for prediction of mortality among patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of cohort study.
        Clin Res Hepatol Gastroenterol. 2017; 41: 629-634
        • Angulo P.
        • Bugianesi E.
        • Bjornsson E.S.
        • et al.
        Simple Noninvasive Systems Predict Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.
        Gastroenterology. 2013; 145 (e4): 782-789
        • Parkes J.
        • Roderick P.
        • Harris S.
        • et al.
        Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease.
        Gut. 2010; 59: 1245-1251
        • Kamath P.S.
        • Mookerjee R.P.
        Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension.
        J Hepatol. 2015; 63: 743-752
        • de Franchis R.
        • Bosch J.
        • Garcia-Tsao G.
        • et al.
        Baveno VII – Renewing consensus in portal hypertension.
        J Hepatol. 2022; 76: 959-974
        • Castéra L.
        • García-Tsao G.
        When the spleen gets tough, the varices get going.
        Gastroenterology. 2013; 144: 19-22
        • Hong W.K.
        • Kim M.Y.
        • Baik S.K.
        • et al.
        The usefulness of noninvasive liver stiffness measurements in predicting clinically significant portal hypertension in cirrhotic patients: Korean data.
        Clin Mol Hepatol. 2013; 19: 370
        • Reiberger T.
        The Value of Liver and Spleen Stiffness for Evaluation of Portal Hypertension in Compensated Cirrhosis.
        Hepatol Commun. 2022; 6: 950-964
        • Berzigotti A.
        • Tsochatzis E.
        • Boursier J.
        • et al.
        EASL Clinical Practice Guidelines on noninvasive tests for evaluation of liver disease severity and prognosis – 2021 update.
        J Hepatol. 2021; 75: 659-689
        • Stafylidou M.
        • Paschos P.
        • Katsoula A.
        • et al.
        Performance of Baveno VI and Expanded Baveno VI Criteria for Excluding High-Risk Varices in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis.
        Clin Gastroenterol Hepatol. 2019; 17 (e11): 1744-1755
        • Szakács Z.
        • Erőss B.
        • Soós A.
        • et al.
        Baveno criteria safely identify patients with compensated advanced chronic liver disease who can avoid variceal screening endoscopy: A diagnostic test accuracy meta-analysis.
        Front Physiol. 2019; 10: 1028
        • You M.W.
        • Kim K.W.
        • Pyo J.
        • et al.
        A Meta-analysis for the Diagnostic Performance of Transient Elastography for Clinically Significant Portal Hypertension.
        Ultrasound Med Biol. 2017; 43: 59-68
        • Podrug K.
        • Trkulja V.
        • Zelenika M.
        • et al.
        Validation of the New Diagnostic Criteria for Clinically Significant Portal Hypertension by Platelets and Elastography.
        Dig Dis Sci. 2022; 67: 3327
        • Kanwal F.
        • Shubrook J.H.
        • Adams L.A.
        • et al.
        Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease.
        Gastroenterology. 2021; 161: 1657-1669
        • Cusi K.
        • Isaacs S.
        • Barb D.
        • et al.
        American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD).
        Endocr Pract. 2022; 28: 528-562
        • De A.
        • Duseja A.
        • Mehta M.
        • et al.
        AGILE 3+ Score for Assessing Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) – Validation in an Indian Cohort.
        J Clin Exp Hepatol. 2022; 12: S65
        • Pennisi G.
        • Enea M.
        • Pandolfo A.
        • et al.
        AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD.
        Clin Gastroenterol Hepatol. 2022; https://doi.org/10.1016/J.CGH.2022.06.013
        • Newsome P.N.
        • Sasso M.
        • Deeks J.J.
        • et al.
        FibroScan-AST (FAST) score for the noninvasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
        Lancet Gastroenterol Hepatol. 2020; 5: 362
        • Woreta T.A.
        • van Natta M.L.
        • Lazo M.
        • et al.
        Validation of the accuracy of the FASTTM score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other noninvasive algorithms.
        PLoS One. 2022; 17: e0266859
        • Noureddin M.
        • Truong E.
        • Gornbein J.A.
        • et al.
        MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis.
        J Hepatol. 2022; 76: 781-787
        • Jung J.
        • Loomba R.R.
        • Imajo K.
        • et al.
        MRE combined with FIB-4 (MEFIB) Index in detection of candidates for pharmacologic treatment of NASH related fibrosis.
        Gut. 2021; 70: 1946
        • Ajmera V.
        • Kim B.K.
        • Yang K.
        • et al.
        Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants.
        Gastroenterology. 2022; https://doi.org/10.1053/J.GASTRO.2022.06.073
        • Kim B.K.
        • Tamaki N.
        • Imajo K.
        • et al.
        Head to head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD.
        J Hepatol. 2022; 13https://doi.org/10.1016/J.JHEP.2022.07.020
        • Vutien P.
        • Berry K.
        • Feng Z.
        • et al.
        Combining FIB-4 and liver stiffness into the FIB-5, a single model that accurately predicts complications of portal hypertension.
        Am J Gastroenterol. 2022; https://doi.org/10.14309/AJG.0000000000001906
        • Terrault N.A.
        • Lok A.S.F.
        • McMahon B.J.
        • et al.
        Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance.
        Hepatology. 2018; 67: 1560
        • Ghany M.G.
        • Morgan T.R.
        Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.
        Hepatology. 2020; 71: 686-721
        • Pawlotsky J.M.
        • Negro F.
        • Aghemo A.
        • et al.
        EASL recommendations on treatment of hepatitis C: Final update of the series.
        J Hepatol. 2020; 73: 1170-1218
        • Lampertico P.
        • Agarwal K.
        • Berg T.
        • et al.
        EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.
        J Hepatol. 2017; 67: 370-398
        • Ioannou G.N.
        HCC surveillance after SVR in patients with F3/F4 fibrosis.
        J Hepatol. 2021; 74: 458-465
        • Carrat F.
        • Fontaine H.
        • Dorival C.
        • et al.
        Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
        The Lancet. 2019; 393: 1453-1464
        • D’Ambrosio R.
        • Degasperi E.
        • Anolli M.P.
        • et al.
        Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR.
        J Hepatol. 2022; 76: 302-310
        • D’Ambrosio R.
        • Aghemo A.
        • Rumi M.G.
        • et al.
        A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis.
        Hepatology. 2012; 56: 532-543
        • Semmler G.
        • Binter T.
        • Kozbial K.
        • et al.
        Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease.
        Hepatology. 2021; 73: 1275-1289
        • Semmler G.
        • Lens S.
        • Meyer E.L.
        • et al.
        Noninvasive tests for clinically significant portal hypertension after HCV cure.
        J Hepatol. 2022; 0https://doi.org/10.1016/J.JHEP.2022.08.025
        • Dulai P.S.
        • Singh S.
        • Patel J.
        • et al.
        Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.
        Hepatology. 2017; 65: 1557-1565
        • Loomba R.
        • Ratziu V.
        • Harrison S.A.
        • et al.
        Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis.
        Gastroenterology. 2022; 162: 680-688
      1. Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment | FDA.
        (Available at:) (Accessed August 21, 2022)
      2. Draft reflection paper on regulatory requirements for the development of medicinal products for chronic non-infectious liver diseases (PBC, PSC, NASH) | European Medicines Agency.
        (Available at:) (Accessed August 21, 2022)
        • Nakajima A.
        • Eguchi Y.
        • Yoneda M.
        • et al.
        Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease.
        Aliment Pharmacol Ther. 2021; 54: 1263
        • Flint A.
        • Andersen G.
        • Hockings P.
        • et al.
        Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging.
        Aliment Pharmacol Ther. 2021; 54: 1150
        • Tamaki N.
        • Munaganuru N.
        • Jung J.
        • et al.
        Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease.
        Gut. 2022; 71: 983-990
        • Stine J.G.
        • Munaganuru N.
        • Barnard A.
        • et al.
        Change in MRI-PDFF and Histologic Response in Patients With Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis.
        Clin Gastroenterol Hepatol. 2021; 19 (e5): 2274-2283